Mirati Therapeutics | MRTX - Операционный доход



Операционный доход Изменить Дата
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amgen USD 3.96B 464M 2025-12
Astellas Pharma JPY 134.54B 30.13B 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Bayer EUR 1.11B 1.65B 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eisai JPY 20.03B 6.36B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Exelixis USD 235.91M 20.45M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Incyte USD 383.88M 47.43M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
J&J USD 5.59B 1.81B 2025-12
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Nektar Therapeutics USD -34.34M 15.43M 2024-09
Novartis USD 4.06B 437M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Roche Holding CHF 9.56B 3.8B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Takeda JPY 168.82B 479.89B 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12